| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Human serum albumin (HSA). Lys(CO‑C3‑p‑I‑Ph)‑OMe binds to albumin, increasing the plasma residence time of conjugated PSMA ligand molecules by reducing their clearance.
|
|---|---|
| ln Vitro |
Lys(CO‑C3‑p‑I‑Ph)‑OMe is a PK modifier that is conjugated to PSMA ligand molecules. Its in vitro activity is measured by the increased binding affinity of the modified PSMA ligand to human serum albumin (HSA). This is assessed by surface plasmon resonance (SPR) or fluorescence polarization assays. By increasing albumin binding, the modified ligand has a longer plasma half‑life and reduced salivary gland uptake.
|
| ln Vivo |
In vivo, Lys(CO‑C3‑p‑I‑Ph)‑OMe is conjugated to PSMA ligands (e.g., Ac‑PSMA‑trillium). The resulting conjugate shows increased residence time in plasma, reduced salivary gland absorption, and an extended half‑life. These improved PK properties enhance the biodistribution and therapeutic index of PSMA‑targeted radionuclide therapies (TRT) for metastatic castration‑resistant prostate cancer (mCRPC).
|
| Enzyme Assay |
A general cell‑free protocol for assessing albumin binding: A surface plasmon resonance (SPR) assay is used. Human serum albumin (HSA) is immobilized on a sensor chip (e.g., CM5 chip via amine coupling). Varying concentrations of the PK modifier (Lys(CO‑C3‑p‑I‑Ph)‑OMe) or the modified PSMA ligand are flowed over the chip in PBS (pH 7.4) at 25degC. The association and dissociation rates are measured, and the equilibrium dissociation constant (Kd) is calculated. For comparison, the unmodified PSMA ligand (without the PK modifier) is also tested. A higher binding affinity (lower Kd) indicates successful PK modification.
|
| Cell Assay |
A general cellular protocol for assessing PSMA binding and internalization: PSMA‑expressing cells (e.g., LNCaP, C4‑2 prostate cancer cells) are seeded in 12‑well plates at 1×10⁵ cells/well. The cells are incubated with a radiolabeled PSMA ligand (e.g., ¹¹¹In‑ or 22⁵Ac‑labeled Ac‑PSMA‑trillium, either unmodified or modified with Lys(CO‑C3‑p‑I‑Ph)‑OMe) at concentrations of 0.1‑10 nM for 1‑4 hours at 37degC. After incubation, cells are washed with cold PBS to remove unbound ligand. The cells are then lysed, and the amount of cell‑associated radioactivity (bound + internalized) is measured using a gamma counter. To determine internalized fraction, cells are acid‑washed (0.1 M glycine, pH 2.5) to remove surface‑bound ligand before lysis.
|
| Animal Protocol |
A general animal protocol for PSMA‑targeted radionuclide therapy: Male NSG mice are subcutaneously or orthotopically implanted with PSMA‑expressing prostate cancer cells (e.g., LNCaP, C4‑2, or 22Rv1). When tumors reach ~100‑200 mm3, mice are randomized into treatment groups (n=6‑10/group). A radiolabeled PSMA ligand (e.g., 22⁵Ac‑Ac‑PSMA‑trillium) that has been modified with Lys(CO‑C3‑p‑I‑Ph)‑OMe is administered via intravenous (IV) injection at doses of 10‑100 kBq per mouse (0.27‑2.7 uCi). For PK studies, the ¹¹¹In‑labeled ligand (a gamma emitter) is used. Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, and 96 hours post‑injection. Radioactivity in plasma and tissues is measured by gamma counting. Biodistribution is assessed by harvesting organs (tumor, liver, spleen, kidney, salivary gland, bone, muscle) at 24, 48, and 96 hours. The PK modifier is expected to increase tumor uptake (via increased plasma exposure) and reduce salivary gland uptake, improving the therapeutic index.
|
| ADME/Pharmacokinetics |
General PK protocol for PSMA ligand modified with Lys(CO‑C3‑p‑I‑Ph)‑OMe: A radiolabeled PSMA ligand (¹¹¹In‑Ac‑PSMA‑trillium) is administered via IV injection to male NSG mice at a dose of 10‑20 uCi/mouse. Blood samples are collected from the tail vein at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 96 hours. Radioactivity in each blood sample is counted using a gamma counter. Blood clearance curves are generated, and PK parameters (Cmax, Tmax, AUC, t½, clearance) are calculated using non‑compartmental analysis. The PK modifier is expected to increase AUC and prolong the half‑life compared to the unmodified ligand.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for PSMA‑targeted radionuclide therapy using Lys(CO‑C3‑p‑I‑Ph)‑OMe: Acute radiation toxicity is the primary concern. A single‑dose study is performed in NSG mice. The radiolabeled ligand (22⁵Ac‑modified or ¹⁷⁷Lu‑modified) is administered IV at escalating doses (e.g., 10, 30, 100, 300, 1000 kBq/mouse). Animals are monitored daily for clinical signs and body weight for 12 weeks. Blood samples are collected weekly for hematology (complete blood count, with special attention to neutrophil and platelet counts) and serum chemistry (ALT, AST, BUN, creatinine). At the end of the study or at humane endpoints, gross necropsy is performed, and histopathology of the kidneys, salivary glands, bone marrow, liver, and spleen is conducted. The maximum tolerated dose (MTD) is determined.
|
| References |
|
| Additional Infomation |
Lys(CO‑C3‑p‑I‑Ph)‑OMe has the molecular formula C1₇H2₅IN2O3 and a molecular weight of 432.30 g/mol. The compound is a modified lysine residue containing a p‑iodophenyl group and a CO‑C3 (propionyl) spacer. It functions as a PK modifier by binding to human serum albumin, which increases the plasma residence time of conjugated PSMA ligands and reduces salivary gland absorption. This technology is being developed for PSMA‑targeted radionuclide therapy (TRT) for metastatic castration‑resistant prostate cancer (mCRPC). When labeled with 22⁵Ac (alpha emitter) or ¹⁷⁷Lu (beta emitter), the modified PSMA ligand can deliver potent radiation to PSMA‑expressing tumors while sparing normal tissues. The compound is stored at -20degC, protected from light.
|
| Molecular Formula |
C17H25IN2O3
|
|---|---|
| Molecular Weight |
432.30
|
| Exact Mass |
432.091
|
| CAS # |
2088426-96-2
|
| PubChem CID |
156847202
|
| Appearance |
Solid powder
|
| Density |
1.411±0.06 g/cm3(Predicted)
|
| Boiling Point |
539.5±50.0 °C(Predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
23
|
| Complexity |
358
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC(=O)[C@H](CCCCNC(=O)CCCC1=CC=C(C=C1)I)N
|
| InChi Key |
VDKOYQQVPOAMHS-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C17H25IN2O3/c1-23-17(22)15(19)6-2-3-12-20-16(21)7-4-5-13-8-10-14(18)11-9-13/h8-11,15H,2-7,12,19H2,1H3,(H,20,21)/t15-/m0/s1
|
| Chemical Name |
methyl (2S)-2-amino-6-[4-(4-iodophenyl)butanoylamino]hexanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (115.66 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3132 mL | 11.5660 mL | 23.1321 mL | |
| 5 mM | 0.4626 mL | 2.3132 mL | 4.6264 mL | |
| 10 mM | 0.2313 mL | 1.1566 mL | 2.3132 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
